Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway

Table 2

Effect of hepatic ischemia/reperfusion (HIR) alone or in combination with intraperitoneal administration of vildagliptin (Vilda) (10 mg/kg for 10 days) on oxidative stress malondialdehyde (MDA) and catalase, nitrosative stress nitric oxide (NO), and inflammatory mediator tumor necrosis factor alpha (TNF-α) levels in the liver of experimental rats. All data were expressed as mean ± SD.

Group	MDA (nmol/mg protein)	Catalase (nmol/min/g tissue)	NO (nmol/mg protein)	TNF-α (pg/mg protein)
Sham	7 ± 0.75	43.1 ± 1.56	2.12 ± 0.52	235 ± 11.57
HIR	24.22 ± 1.96	18.08 ± 1.5	7.8 ± 0.57	818.2 ± 75.44
Vilda + HIR	15.56 ± 0.8	29.8 ± 3.29	5.02 ± 0.37	431.1 ± 63.2

^aSignificant difference from the sham group at . ^bSignificant difference from the HIR group at .